| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2912 |
| Trial ID | NCT05212610 |
| Disease | COVID-19 | Coronavirus Infectious Disease |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT162b2|COMIRNATY|Tozinameran |
| Location approved | UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia |
| Phase | Phase4 |
| Recruitment status | Recruiting |
| Title | Assessing Safety of COVID-19 mRNA Vaccine Administration in the Setting of a Previous Adverse Reaction |
| Year | 2022 |
| Country | United States |
| Company sponsor | University of Michigan |
| Other ID(s) | HUM00206480 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||
|
|||||||